Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
8.88
-0.34 (-3.69%)
At close: Mar 28, 2025, 4:00 PM
9.45
+0.57 (6.42%)
After-hours: Mar 28, 2025, 6:06 PM EDT
Myriad Genetics Employees
Myriad Genetics had 2,700 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
2,700
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$310,222
Profits / Employee
-$47,148
Market Cap
810.82M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MYGN News
- 4 weeks ago - Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO - Benzinga
- 4 weeks ago - Myriad Genetics, Inc. (MYGN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth - GlobeNewsWire
- 4 weeks ago - Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio - GlobeNewsWire
- 5 weeks ago - Myriad Genetics Included in Forbes America's Best Employers 2025 List - GlobeNewsWire
- 7 weeks ago - Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test - GlobeNewsWire
- 7 weeks ago - Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay - GlobeNewsWire
- 7 weeks ago - Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration - GlobeNewsWire